Inpegsomatropin
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Inpegsomatropin
- inpegsomatropin
- Inpegsomatropin
- inpegsomatropin [INN]
- Inpegsomatropin [WHO-DD]
- inpegsomatropin injection
- Inpegsomatropin Injection
- inpegsomatropin inn
- inpegsomatropin who dd
- Inpegsomatropin-Injection
- inpegsomatropina
- Inpegsomatropina
- inpegsomatropine
- Inpegsomatropine
- Recombinant human somatotropin (growth hormone, GH), conjugated to a multi-arm polyethylene glycol carrier molecule (somatotropin (human), produced by Pichia pastoris, non-glycosylated, N-terminal or N6.Lys mono-substituted with one (2-[ω-methoxypoly(oxyethylene)-α-yl]-N-{2-[ω-methoxypoly(oxyethylene)-α-yl]ethyl}acetamido)acetyl group (~40 kDa)
- recombinant human somatotropin growth hormone gh conjugated to a multi arm polyethylene glycol carrier molecule somatotropin human produced by pichia pastoris non glycosylated n terminal or n6 lys mono substituted with one 2 ω methoxypoly oxyethylene α yl n 2 ω methoxypoly oxyethylene α yl ethyl acetamido acetyl group 40 kda
- Somatotropin (recombinant human), 1(38,70,140,145 or 158)-amide with α-hydro-ω-methoxypoly(oxy-1,2-ethanediyl) ether with N-(2-hydroxyacetyl)-N-(2-hydroxyethyl)glycine (2:1)
- somatotropin recombinant human 1 38 70 140 145 or 158 amide with α hydro ω methoxypoly oxy 1 2 ethanediyl ether with n 2 hydroxyacetyl n 2 hydroxyethyl glycine 2 1
- CAS registry numbers
- 2656386-75-1
- ChEMBL ID
- CHEMBL5314747
- FDA ingredient codes (UNII)
- NUB86ZJ8XT
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -peg-; -pin; -trop-
Open Targets indications
- Condition identifier
- HP_0004322
- Highest recorded phase
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
- Component
- Sequence
- Type
- Protein
- Sequence
- FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF
- Component
- Disulfide bridges
- Sequence
- 53-165 $ 182-189
Related records
Trials (1,754)
- [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
- 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
- 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
- 18F-PBR06/Total Body PET Imaging in Patients With STEMI
- 3D1015 Injection for Patients With mCRPC
- 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
- 68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis
- 68Ga-GP-01 Injection in Solid Tumors Participants
- 99Tc-MDP for Thyroid-Associated Ophthalmopathy
- A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
- A Bioequivalence Study of Two Different Dosage Form of Genakumab
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection
- A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
- A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
- A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
- A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
- A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors